Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide Attempts

Sponsor
Oui Therapeutics, LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT04295382
Collaborator
(none)
15
1
1
13.6
1.1

Study Details

Study Description

Brief Summary

The primary objective of this feasibility study is to assess the feasibility, and usability of a software application to deliver targeted interactive exercises to patients recently hospitalized for suicidal ideation or suicide attempts.

Condition or Disease Intervention/Treatment Phase
  • Device: Software Application
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
An Open-Label, Study of the Feasibility and the Usability of a Software Application to Deliver Targeted Interactive Exercises, in Addition to Treatment as Usual, to Patients Recently Hospitalized for Suicidal Ideation or Suicide Attempts
Actual Study Start Date :
May 12, 2020
Actual Primary Completion Date :
Jul 1, 2021
Actual Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Software Application

Device: Software Application
A software application targeting suicidal ideation via interactive exercises.

Outcome Measures

Primary Outcome Measures

  1. System Usability Scale (SUS) [16 weeks]

    The SUS is a valid and reliable, 10-item measure that effectively differentiates between usable and unusable systems. Sample items are "I think that I would like to use this app frequently" and "I felt very confident using the system." Responses are rated using a 5-point (strongly disagree to strongly agree) Likert scale. Scores range from 0 to 100, with a score of 68 being minimal indicator of usability.

  2. User Feedback Interview Questions [16 weeks]

    Participants will answer the following questions. 1) What did you think about this experience? 2) Do you think you would use this app again if needed? Why (not)? 3) Do you think this app would be useful for helping you with your suicidal thoughts and preventing you from acting on them? Why (not)? Did you think functions were missing in the app? Which ones? 4) Is there anything else you think we should know to make this app better and more user-friendly?

Secondary Outcome Measures

  1. Suicidal ideation [16 weeks]

    The Beck Scale for Suicidal Ideation (BSS) is a 21-item self or clinician administered instrument used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.

  2. Suicide attempts and other behaviors [16 weeks]

    This outcome will be assessed via the Columbia Suicide Severity Rating Scale (CSSRS), which was designed to classify suicide attempts, aborted suicide attempts, and other suicidal behaviors. Intensity of Ideation Subscale - includes 5 questions about the Frequency, Duration, Controllability, Deterrents, and Reasons for Ideation for the most severe level of ideation endorsed on the Severity subscale (i.e., highest endorsed from 1 to 5). The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk. Suicidal Behavior Lethality inquires about the level of actual medical damage or potential for it. Greater lethality or potential lethality of the behavior (endorsed on the Behavior subscale) indicates increased risk.

  3. Diagnostic interview [1 week]

    The Mini International Neuropsychiatric Interview Neurocognitive (MINI) (40): this is a widely used, structured diagnostic interview that will be used to verify diagnosis at the screening visit.

  4. Adverse events [16 weeks]

    The Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI): This is a self-rated questionnaire assessing possible adverse events during the course of the trial. The purpose of the SAFTEE-SI is analytical and evaluates adverse events on a study level.

  5. Depressive symptoms [16 weeks]

    The Patient Health Questionnaire (PHQ-9) is a 9-item self-report form to assess the severity of depressive symptoms that has been widely used in practice and research. This will be used throughout the study to assess severity of any depressive symptoms each participants is experiencing. The possible range is 0-27. Minimal depression (0-4). ≤ 4 The score suggests the patient may not need depression treatment. Mild depression (5-9). Moderate depression (10-14). 5 - 14 Physician uses clinical judgment about treatment, based on patient's duration of symptoms and functional impairment. Moderately severe depression (15-19). Severe depression (20-27). > 14 Warrants treatment for depression, using antidepressant, psychotherapy and/or a combination of treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • English speaking male or female patients, 18-70 years

  • Patients who have attempted suicide and voluntarily admitted themselves to an inpatient psychiatric unit or have clinically significant suicidal ideation and intent to harm themselves and are still on the inpatient psychiatric unit.

  • Understand written and spoken English

  • Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher

  • Willing and able to complete enrollment procedures

  • Able to understand the nature of the study and provide written informed consent

  • Able and willing to provide at least two verifiable contacts for emergency or tracking purposes.

Exclusion Criteria:
  • Patients with active psychosis

  • Patients who are acutely intoxicated at the time of enrollment

  • Currently enrolled in other treatment studies for the symptoms and behaviors targeted

  • Patients who are cognitively impaired

  • Patients who, in the judgment of the investigator, would have an unfavorable risk/benefit (e.g. critically ill patients) profile with respect to the software application that delivers interactive exercises.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale-New Haven Hospital New Haven Connecticut United States 06519

Sponsors and Collaborators

  • Oui Therapeutics, LLC

Investigators

  • Principal Investigator: Sam Wilkinson, M.D., Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oui Therapeutics, LLC
ClinicalTrials.gov Identifier:
NCT04295382
Other Study ID Numbers:
  • OUI-AVI-BT3
First Posted:
Mar 4, 2020
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022